Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Apr 22;87(6):3756-3767.
doi: 10.1097/MS9.0000000000003264. eCollection 2025 Jun.

Efficacy and safety of pemafibrate administration in patients with dyslipidemia: a systematic review and updated meta-analysis of randomized controlled trials

Mohammed A Elbahloul  1 , Ammar Elgadi  2 , Mohamed Ramadan  3 , Houssaini Mohamed Amine  4 , Hossam Fayed  5 , Mohamed E Kasser  1 , Ahmed Hussein  6 , Fatma Labieb  7
Affiliations
Review

Efficacy and safety of pemafibrate administration in patients with dyslipidemia: a systematic review and updated meta-analysis of randomized controlled trials

Mohammed A Elbahloul et al. Ann Med Surg (Lond). .

Abstract

Background: Patients with dyslipidemia are at risk for cardiovascular diseases. Lowering levels of lipid decrease morbidity. Pemafibrate is a selective peroxisome proliferator-activated receptor α modulator (SPPARMα) that works better at lowering serum triglycerides.

Methods: Clinical trials investigating the effect of pemafibrate on lipid biomarkers in patients with dyslipidemia were searched in PubMed, Ovid Medline, SCOPUS, Web of Science (WOS), and the Cochrane Library from inception till 31 December 2023. The data were pooled as mean difference, odds ratio (OR), and 95% confidence interval (CI).

Results: 14 clinical trials were eligible, involving 12 451 patients, and showed favorable triglyceride level change (MD: -49.60 [-62.64, -36.55] P < 0.00001) for pemafibrate compared to placebo. Pemafibrate showed a significant increase in HDL-C levels (MD: 14.57 [10.14, 19.01] P < 0.00001) but showed a concurrent increase in LDL-C levels (MD: 10.99 [6.10, 15.88] P < 0.00001). It also showed non-HDL-C, total cholesterol level, Apo B, Apo C-II, and Apo C-III to be significantly reduced in pemafibrate groups. Also, in pemafibrate groups, hepatic adverse events were reported less frequently than in placebo groups. No significant difference was found in the frequency of total adverse effects, adverse drug reactions, or serious adverse events between the pemafibrate and placebo groups.

Conclusion: Pemafibrate improved the overall lipid biomarkers compared to placebo groups, demonstrating a significant reduction in triglycerides, non-HDL-C, and total cholesterol while increasing HDL-C. Moreover, there was no significant difference in adverse effects.

Keywords: adverse events; dyslipidemia; lipid biomarkers; other fibrates; pemafibrate.

PubMed Disclaimer

Conflict of interest statement

Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article. All authors have no disclosures or conflict of interests.

Figures

Figure 1.
Figure 1.
PRISMA flowchart.
Figure 2.
Figure 2.
Risk of bias according to cochrane risk of bias tool (version 2).
Figure 3.
Figure 3.
Forest plot presenting MD for the effect of pemafibrate VS placebo on TGs.
Figure 4.
Figure 4.
Forest plot presenting MD for the effect of pemafibrate VS other fibrates on TGs.
Figure 5.
Figure 5.
Forest plot presenting OR for effect of pemafibrate VS placebo on total AEs.
Figure 6.
Figure 6.
Forest plot presenting OR for effect of pemafibrate VS other fibrates on total AEs.
See this image and copyright information in PMC

References

    1. Roth GA, Mensah GA, Johnson CO, et al. Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 study. J Am Coll Cardiol 2020;76:2982–3021. - PMC - PubMed
    1. Peters SAE, Singhateh Y, Mackay D, et al. Total cholesterol as a risk factor for coronary heart disease and stroke in women compared with men: a systematic review and meta-analysis. Atherosclerosis 2016;248:123–31. - PubMed
    1. Reiner Ž. Hypertriglyceridaemia and risk of coronary artery disease. Nat Rev Cardiol 2017;14:401–11. - PubMed
    1. Du Z, Qin Y. Dyslipidemia and cardiovascular disease: current knowledge, existing challenges, and new opportunities for management strategies. J Clin Med 2023;12:363. - PMC - PubMed
    1. Raja V, Aguiar C, Alsayed N, et al. Non-HDL-cholesterol in Dyslipidemia: Review of the State-of-the-art Literature and Outlook‏. Elsevier; cited 2024 Dec 18. Available from. https://www.sciencedirect.com/science/article/pii/S0021915023052334. - PubMed

LinkOut - more resources